Adachi T, Asano K, Sezaki T, Takahashi I, Kimura I
Acta Med Okayama. 1982 Feb;36(1):39-47. doi: 10.18926/AMO/30707.
Response rates and survival times were studied in 47 patients who had multiple myeloma and who were being treated with Prednisolone and sequential Melphalan and Ifosfamide (MIP therapy). The clinical response was determined by objective parameters such as the reduction of M-protein level, tumor volume and healing of bone destruction. Twenty-eight of the patients (59.6%) responded to the MIP therapy. The 50% survival time as followed from the initiation of treatment to death was 19 months. Of the prognostic factors, the age (greater than or equal to 70 years), clinical stage III of Durie and Salmon, hypercalcemia, extensive bone lesions, and the patho-morphological type IV of Brücher were associated with a decreased life-span. Therefore, MIP therapy was more effective in poor risk (high tumor mass group) than in good risk (low or intermediate tumor mass group) patients, but the survival of patients on MIP therapy was shorter in the poor risk group than in the good risk one. In addition, the group which responded rapidly (i.e. within 2-5 weeks) had longer remission and longer survival than the group which improved slowly (i.e. after 6-16 weeks).
对47例患有多发性骨髓瘤且正在接受泼尼松龙以及序贯美法仑和异环磷酰胺（MIP疗法）治疗的患者的缓解率和生存时间进行了研究。临床反应通过客观参数来确定，如M蛋白水平降低、肿瘤体积缩小和骨破坏愈合情况。28例患者（59.6%）对MIP疗法有反应。从治疗开始到死亡的50%生存时间为19个月。在预后因素中，年龄（大于或等于70岁）、Durie和Salmon临床分期III期、高钙血症、广泛的骨病变以及Brücher病理形态学IV型与寿命缩短相关。因此，MIP疗法在预后不良（高肿瘤负荷组）患者中比在预后良好（低或中等肿瘤负荷组）患者中更有效，但MIP疗法治疗的患者在预后不良组中的生存期比预后良好组更短。此外，快速反应组（即2 - 5周内）的缓解期和生存期比缓慢改善组（即6 - 16周后）更长。
